低分子肝素辅助治疗不稳定型心绞痛73例临床分析  

Clinical analysis of 73 cases of unstable angina pectoris treated with low molecular weight heparin

作　　者：陈倩[1] 胡卫民[1] 刘盛辉[1] 

机构地区：[1]北京市房山区良乡医院

出　　处：《首都食品与医药》2020年第2期6-7,共2页Capital Food Medicine

摘　　要：目的观察低分子肝素治疗不稳定型心绞痛(UA)73例的疗效及预后。方法以2016年10月~2018年10月收治的73例UA患者为研究对象,根据治疗方式不同随机分为治疗组38例和对照组35例,均予扩张冠状动脉、抗血小板聚集、心肌保护等常规治疗,治疗组在此基础上给予低分子肝素皮下注射,疗程7d。观察两组临床疗效并随访心脏事件发生情况。结果治疗组显效率、总有效率均明显高于对照组,差异显著。治疗组PT和APTT明显高于对照组,随访3个月心脏事件发生率明显低于对照组(P<0.05)。结论低分子肝素辅助治疗不稳定心绞痛效果显著,不良反应少,能明显改善患者预后。Objective To observe the efficacy and prognosis of unstable angina(UA)treated with low molecular weight heparin in 73 cases. Methods 73 cases with UA who admitted from October 2016 to October 2018 were studied. According to the different treatment they were randomly divided into treatment group(38 cases) and control group(35 cases).All patients were given routine treatment such as expansion of coronary artery, antiplatelet aggregation and myocardial protection. The treatment group was injected with low molecular weight heparin in subcutaneous for 7 days on routine treatment. The clinical effects of the two groups were observed and the occurrence of cardiac events was followed up. Results The marked efficiency and total efficiency of the treatment group were significantly higher than those of the control group, with significant difference. PT and APTT in the treatment group were significantly higher than those in the control group, and the incidence of cardiac events in the follow-up period of 3 months was significantly lower than that in the control group(P<0.05). Conclusion Low molecular weight heparin is an effective adjuvant therapy for unstable angina pectoris, with fewer adverse reactions, and can significantly improve the prognosis of patients.

关 键 词：低分子肝素 不稳定心绞痛 预后 

分 类 号：R972[医药卫生—药品]